Stephen R Grant1, Benjamin D Smith1, Anna O Likhacheva2, Shervin M Shirvani2, David B Rosen3, B Ashleigh Guadagnolo1, Dean A Shumway4, Emma B Holliday1, Daniel Chamberlain2, Gary V Walker5. 1. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 2. Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona. 3. College of Medicine, The University of Arizona Health Sciences, Phoenix, Arizona. 4. Department of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan. 5. Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona. Electronic address: Gary.Walker@bannerhealth.com.
Abstract
BACKGROUND: In this study, we sought to examine the variation in intensity modulated radiation therapy (IMRT) use among radiation oncology providers. METHODS AND MATERIALS: The Medicare Physician and Other Supplier Public Use File was queried for radiation oncologists practicing during 2014. Healthcare Common Procedural Coding System code 77301 was designated as IMRT planning with metrics including number of total IMRT plans, rate of IMRT utilization, and number of IMRT plans per distinct beneficiary. RESULTS: Of 2759 radiation oncologists, the median number of total IMRT plans was 26 (mean, 33.4; standard deviation, 26.2; range, 11-321) with a median IMRT utilization rate of 36% (mean, 43%; standard deviation, 25%; range, 4% to 100%) and a median number of IMRT plans per beneficiary of 1.02 (mean, 1.07; range, 1.00-3.73). On multivariable analysis, increased IMRT utilization was associated with male sex, academic practice, technical fee billing, freestanding practice, practice in a county with 21 or more radiation oncologists, and practice in the southern United States (P < .05). The top 1% of users (28 providers) billed a mean 181 IMRT plans with an IMRT utilization rate of 66% and 1.52 IMRT plans per beneficiary. Of these 28 providers, 24 had billed technical fees, 25 practiced in freestanding clinics, and 20 practiced in the South. CONCLUSIONS: Technical fee billing, freestanding practice, male sex, and location in the South were associated with increased IMRT use. A small group of outliers shared several common demographic and practice-based characteristics.
BACKGROUND: In this study, we sought to examine the variation in intensity modulated radiation therapy (IMRT) use among radiation oncology providers. METHODS AND MATERIALS: The Medicare Physician and Other Supplier Public Use File was queried for radiation oncologists practicing during 2014. Healthcare Common Procedural Coding System code 77301 was designated as IMRT planning with metrics including number of total IMRT plans, rate of IMRT utilization, and number of IMRT plans per distinct beneficiary. RESULTS: Of 2759 radiation oncologists, the median number of total IMRT plans was 26 (mean, 33.4; standard deviation, 26.2; range, 11-321) with a median IMRT utilization rate of 36% (mean, 43%; standard deviation, 25%; range, 4% to 100%) and a median number of IMRT plans per beneficiary of 1.02 (mean, 1.07; range, 1.00-3.73). On multivariable analysis, increased IMRT utilization was associated with male sex, academic practice, technical fee billing, freestanding practice, practice in a county with 21 or more radiation oncologists, and practice in the southern United States (P < .05). The top 1% of users (28 providers) billed a mean 181 IMRT plans with an IMRT utilization rate of 66% and 1.52 IMRT plans per beneficiary. Of these 28 providers, 24 had billed technical fees, 25 practiced in freestanding clinics, and 20 practiced in the South. CONCLUSIONS: Technical fee billing, freestanding practice, male sex, and location in the South were associated with increased IMRT use. A small group of outliers shared several common demographic and practice-based characteristics.
Authors: Ryan J Hutten; Chris R Weil; David K Gaffney; Kristine Kokeny; Shane Lloyd; Charles R Rogers; Gita Suneja Journal: Adv Radiat Oncol Date: 2022-01-20
Authors: Luca F Valle; Fang-I Chu; Palak Kundu; Stephanie M Yoon; Travis Gilchrist; Michael L Steinberg; Ann C Raldow Journal: Cancer Med Date: 2021-06-02 Impact factor: 4.452